Sol-Gel signs $27m dermatology drug deal in US

Sol-Gel already has a $25 million dermatology drug development and licensing agreement with the same company.

Sol-Gel Technologies Ltd. has signed a $27 million development and licensing agreement with a US pharmaceutical company. This is the company's second agreement with a US pharmaceutical company for the development and commercialization in the US and Canada of a dermatologic drug.

Sol-Gel will receive a non-refundable payment, licensing fees, milestone payments, and royalties on future net sales. The US company will finance the product's development.

Sol-Gel already has a $25 million dermatology drug development and licensing agreement with the same company.

Sol-Gel CEO Dr. Alon Seri-Levy and Prof. David Avnir of the Hebrew University of Jerusalem founded the company in 1997 based on micro-encapsulation performed through silica chemical processes. Based in Ness Ziona, it develops dermatology drugs delivered by patented systems designed to enhance the efficacy and safety of topical drugs. The company has five products in its pipeline, ranging from the preclinical stage through the registration stage for its acne treatment.

Investors include Jerusalem Venture Partners (JVP), Medica Venture Partner, Millennium Material Technologies Fund, Challenge Fund - Etgar, Evergreen Venture Partners, Argonaut Private Equity, DSM Venturing, and the Jesselson Family Fund.

Seri-Levy said, "This repeat collaboration reinforces Sol-Gel’s position as a leading player in the development of encapsulation technologies for application to topical drug products."

Published by Globes [online], Israel business news - www.globes-online.com - on February 21, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס